In IDH-mutated low-grade gliomas, IFN signaling undergoes epigenetic hypermethylation-mediated suppression, a process reversible by MGMT inhibitors or IDH antagonists, reactivating the IFN pathway. The gene discussed is IDH2; the disease is low grade glioma.